Anti-Human PD-L1 (CD274) [Clone 29E.2A3] — Purified in vivo PLATINUM™ Functional Grade
Anti-Human PD-L1 (CD274) [Clone 29E.2A3] — Purified in vivo PLATINUM™ Functional Grade
Product No.: P603
Clone 29E.2A3 Target PD-L1 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names CD274, B7-H1, Programmed death-ligand 1 Isotype Mouse IgG2b κ Applications B , FA , FC , IHC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Full length Human PD-L1 Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 0.5 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥98% monomer by analytical SEC Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? B, FA, IHC, FC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Human PD-L1 (CD274) Background Programmed cell death 1 ligand 1 (PD-L1; CD274; B7-H1) is a type I transmembrane glycoprotein widely expressed in many types of tissues that acts as a ligand for the immune inhibitory receptor programmed cell death 1 (PD-1; CD279)1, 2, 3. The PD-1 pathway is responsible for T cell activation, proliferation, and cytotoxic secretion, with PD-1/PD-L1 interaction triggering inhibitory signals that dampen T cell function. PD-L1 also plays a critical role in the differentiation of inducible regulatory T cells4. In normal tissues, PD-L1/PD-1 ligation is crucial to maintaining homeostasis of the immune system and preventing autoimmunity during infection and inflammation4. In the tumor microenvironment, their interaction provides an immune escape mechanism for tumor cells by turning off cytotoxic T cells. As such, blocking the PD-L1/PD-1 interaction is a target of many anti-cancer immunotherapies. 29E.2A3 was generated by immunizing female BALB/c mice with purified hPD-L1 cDNA5. Spleen cells were fused with SP2/0 myeloma cells, and the resulting hybridomas were screened by ELISA for reactivity against hPD-L1–Ig fusion protein followed by cell-surface staining of hPD-L1–transfected Chinese hamster ovary cells and 300.19 cells. Antigen Distribution PD-L1 is commonly expressed on the surface of antigen presenting cells (macrophages, activated B cells, dendritic cells), some epithelial cells under inflammatory conditions, some activated T cells, and several types of tumors as well as tumor infiltrating immune cells. PD-L1 can also exist in a soluble form (sPD-L1) in myeloid-derived cells (monocytes, macrophages, and dendritic cells) and several human cancer lines. Ligand/Receptor PD-1 (CD279) NCBI Gene Bank ID UniProt.org Q9NZQ7 Research Area Apoptosis . Cancer . Cell Biology . Cell Death . Immunology . Inhibitory Molecules . Tumor Suppressors Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 29E.2A3 is most commonly used in mice for in vivo blockade of human PD-L1 signaling to study immune checkpoint inhibition and tumor immunology. This approach helps researchers analyze the functional role of PD-L1 in tumor immune escape, T cell regulation, and responses to immunotherapy, especially in the context of humanized mouse models expressing human PD-L1. Typical in vivo applications in mice include:
Key contextual points:
In summary, clone 29E.2A3 is a tool of choice in mouse models—particularly humanized— for studying the immunobiology of human PD-L1, testing immune checkpoint blockade efficacy, and elucidating mechanisms of antitumor immunity. Commonly used antibodies or proteins paired with 29E.2A3 (an anti-human PD-L1/CD274 antibody) in the literature include several secondary detection antibodies, immune checkpoint markers, and lineage-specific immune markers. These are often utilized for multi-color flow cytometry, blocking assays, and immunofluorescence. Key commonly used antibodies or proteins with 29E.2A3:
Summary table of commonly used antibodies/proteins with 29E.2A3:
In summary, 29E.2A3 is commonly used with secondary detection reagents and various immune markers—particularly those related to T cell checkpoints (PD-1, CTLA-4) and lineage markers—in both phenotype and functional studies. Clone 29E.2A3, an anti-human PD-L1 (CD274/B7-H1) antibody, has generated significant findings across multiple areas of immunology research. This widely-used antibody clone has been instrumental in advancing our understanding of PD-L1 biology, but has also revealed important technical considerations for its use. Functional Characterization and ApplicationsClone 29E.2A3 recognizes an epitope on PD-L1 within the PD-L1-CD80 binding region. This positioning makes it particularly valuable for functional studies, as it has demonstrated blocking capabilities in multiple experimental contexts. The antibody has been successfully employed in various applications including flow cytometry, immunohistochemical staining of acetone-fixed frozen sections, and blocking assays. However, it notably does not work in Western blot applications. The scientific literature includes several key studies utilizing this clone. Research by Brown et al. (2003) employed 29E.2A3 for flow cytometry, immunohistochemistry, and blocking experiments. Subsequent studies by Radziewicz et al. (2007) and Nakamoto et al. (2009) used the antibody in blocking assays to investigate PD-L1 function. More recent work by Barsoum et al. (2014) and Mahoney et al. (2015) continued to leverage this clone for cancer research applications. Critical Discovery of Fluorophore Cross-ReactivityA particularly important finding emerged regarding an unexpected interaction between clone 29E.2A3 and the Alexa Fluor 700 (AF700) fluorophore. Research demonstrated that this antibody clone can bind directly to AF700 fluorescent conjugates during multi-color immunofluorescent staining. This discovery came from careful validation studies examining PD-L1 expression on neutrophils. When investigating PD-L1 expression on neutrophils from healthy volunteers and COPD patients, researchers initially observed increased PD-L1 detection when using AF700-conjugated anti-CD16 antibodies alongside clone 29E.2A3. However, this turned out to be an artifact. Co-staining experiments with AF700-conjugated IgG1κ and clone 29E.2A3 revealed a reduction in detected PD-L1 expression, indicating that the PD-L1 antibody was binding directly to the AF700 fluorochrome rather than detecting genuine biological PD-L1 expression. This was confirmed by comparing clone 29E.2A3 with an alternative PD-L1 clone (130,021 from R&D Systems). While clone 29E.2A3 produced false-positive PD-L1 detection in combination with AF700-conjugated anti-CD16, clone 130,021 did not reproduce this effect. The interaction was further supported by small decreases in the detected mean fluorescence intensity (MFI) of AF700 in the presence of clone 29E.2A3, likely due to disruption of the fluorescence signal from direct antibody binding to the fluorophore. Practical Implications and RecommendationsTo address the fluorophore binding issue, researchers can use sequential staining protocols—staining with the 29E.2A3 antibody first, followed by the AF700 conjugate of interest. This workflow resolves the interaction and prevents false-positive results. The discovery of this fluorophore cross-reactivity represents a novel mode of antibody cross-reactivity that extends beyond typical antigen-antibody interactions. This finding emphasizes the critical importance of rigorous antibody validation in multi-color flow cytometry panels, particularly when using new combinations of clones, fluorophores, and binding targets. The use of appropriate controls, such as fluorescence minus one (FMO) controls, is essential for identifying false-positive results. Expression Pattern StudiesClone 29E.2A3 has been extensively used to characterize PD-L1 expression patterns across various cell types and disease states. Studies have analyzed PD-L1 expression in 19 human tumor cell lines using this clone, categorizing surface expression as low, medium, or high. PD-L1 is expressed constitutively on macrophages and dendritic cells, and can be induced on activated T cells, B cells, endothelial cells, and epithelial cells in response to interferons alpha, beta, and gamma. Research has also found abundant PD-L1 expression on many murine and human cancers, with further upregulation possible upon IFN-gamma stimulation. These collective findings establish clone 29E.2A3 as both a valuable research tool and a cautionary example of the need for thorough antibody validation in immunological research. OverviewThe clone 29E.2A3 specifically targets human PD-L1 (CD274, B7-H1) and is primarily used for in vitro assays, epitope mapping, and detecting human PD-L1 expression in research applications. There is no established or standardized dosing regimen for clone 29E.2A3 in mouse models reported in the literature, as its direct therapeutic use is rare—most in vivo studies using PD-L1 blockade in mice employ anti-mouse PD-L1 clones (such as 10F.9G2). Current Understanding
Summary Table
Key Points
ConclusionDosing regimens for clone 29E.2A3 are not established across mouse models and, given its specificity for human PD-L1, it is not used for immune checkpoint blockade in standard mouse studies. Researchers should use species-matched antibodies for functional studies and consult product-specific resources for any intended in vivo use of 29E.2A3 in specialized humanized systems. References & Citations1. Freeman GJ, Long AJ, Iwai Y, et al. J Exp Med. 2000192(7):1027-1034. 2000. 2. Tsai KK, Zarzoso I, Daud AI. Hum Vaccin Immunother. 10(11):3111-3116. 2014. 3. Han Y, Liu D, Li L. Am J Cancer Res. 10(3):727-742. 2020. 4. Dermani FK, Samadi P, Rahmani G, et al. J Cell Physiol. 234(2):1313-1325. 2019. 5. Latchman Y, Wood CR, Chernova T, et al. Nat Immunol. 2(3):261-268. 2001. 6. Brown JA, Dorfman DM, Ma FR, et al. J Immunol. 170(3):1257-1266. 2003. 7. Cai G, Karni A, Oliveira EM, et al. Cell Immunol. 230(2):89-98. 2004. 8. Porichis F, Hart MG, Zupkosky J, et al. J Virol. 88(5):2508-2518. 2014. 9. Hughes MJ, McGettrick HM, Sapey E. J Immunol Methods. 483:112795. 2020. 10. Boyerinas B, Jochems C, Fantini M, et al. Cancer Immunol Res. 3(10):1148-1157. 2015. 11. Nakamoto N, Cho H, Shaked A, et al. PLoS Pathog. 5(2):e1000313. 2009. 12. Hegde S, Lockridge JL, Becker YA, et al. J Autoimmun. 37(1):28-38. 2011. 13. Broos K, Lecocq Q, Keersmaecker B, et al. Vaccines (Basel). 7(3):85. 2019. 14. Darga EP, Dolce EM, Fang F, et al. PLoS One. 16(11):e0260124. 2021. Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
P604 | |
P611 | |
P609 | |
P610 | |
P602 | |
P605 | |
P606 | |
P607 | |
P608 | |
P603 |
